KABRADG

Kabra Drugs Share Price

₹9.14
05 November, 2024 08:52 BSE: 524322 NSE: KABRADG ISIN: INE323K01017

Start SIP in Kabra Drugs

Start SIP

Kabra Drugs Performance

Day Range

  • Low 0
  • High 0
₹ 9

52 Week Range

  • Low 0
  • High 0
₹ 9
  • Open Price0
  • Previous Close0
  • Volume

Kabra Drugs Chart

  • Over 1 Month 0%
  • Over 3 Month + 10.12%
  • Over 6 Month + 27.12%
  • Over 1 Year + 61.48%

Kabra Drugs Key Statistics

Kabra Drugs Financials
IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
Oper Rev Qtr Cr 000000
Operating Expenses Qtr Cr 100000
Operating Profit Qtr Cr -100000
Depreciation Qtr Cr 000000
Interest Qtr Cr 000000
Tax Qtr Cr 000000
Net Profit Qtr Cr -100000
IndicatorMar 2024Mar 2023
Total Revenue Annual Cr 00
Operating Expenses Annual Cr 10
Operating Profit Annual in Cr -10
Depreciation Cr 00
Interest Annual Cr 00
Tax Annual Cr 00
Net Profit Annual Cr -10
IndicatorMar 2024Mar 2023
Cash from Operating Activity Annual Cr 00
Cash from Investing Activity Annual Cr
Cash from Financing Annual Activity Cr 30
Net Cash Flow Annual Cr 30
IndicatorMar 2024Mar 2023
Total ShareHolders Funds Annual Cr -1-1
Fixed Assets Annual Cr 00
Total Non Current Assets Annual Cr 00
Total Current Assets Annual Cr 51
Total Assets Annual Cr 51
IndicatorMar 2024Mar 2023
Book Value Per Share Annual Rs -3-2
ROE Annual % 00
ROCE Annual % -6846
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 00
IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
Oper Rev Qtr Cr
Operating Expenses Qtr Cr
Operating Profit Qtr Cr
Depreciation Qtr Cr
Interest Qtr Cr
Tax Qtr Cr
Net Profit Qtr Cr
IndicatorMar 2024Mar 2023
Total Revenue Annual Cr
Operating Expenses Annual Cr
Operating Profit Annual in Cr
Depreciation Cr
Interest Annual Cr
Tax Annual Cr
Net Profit Annual Cr
IndicatorMar 2024Mar 2023
Cash from Operating Activity Annual Cr
Cash from Investing Activity Annual Cr
Cash from Financing Annual Activity Cr
Net Cash Flow Annual Cr
IndicatorMar 2024Mar 2023
Total ShareHolders Funds Annual Cr
Fixed Assets Annual Cr
Total Non Current Assets Annual Cr
Total Current Assets Annual Cr
Total Assets Annual Cr
IndicatorMar 2024Mar 2023
Book Value Per Share Annual Rs
ROE Annual %
ROCE Annual %
Total Debt to Total Equity Annual --
EBDIT Annual Margin %

Kabra Drugs Technicals

EMA & SMA

Current Price
₹9.14
+ 0 (0%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • ₹8.57
  • 50 Day
  • ₹7.45
  • 100 Day
  • ₹6.43
  • 200 Day
  • ₹5.48
  • 20 Day
  • ₹8.58
  • 50 Day
  • ₹7.22
  • 100 Day
  • ₹5.93
  • 200 Day
  • ₹5.18

Kabra Drugs Resistance and Support

PIVOT
₹9.14
Resistance
First Resistance 9.14
Second Resistance 9.14
Third Resistance 9.14
RSI 93.79
MFI 100.00
MACD Single Line 0.63
MACD 0.60
Support
First Support 9.14
Second Support 9.14
Third Supoort 9.14

Kabra Drugs Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 150 15,000 100
Week 150 15,000 100
1 Month
6 Month 1,052 105,233 100

Kabra Drugs Result Highlights

Kabra Drugs Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Kabra Drugs Corporate Action

Date Purpose Remarks
2024-11-04 Others
2024-08-14 Quarterly Results
2024-07-12 Others Inter alia, 1. To consider and change the registered office of the Company within the local limits of city where the registered office of the company is presently situated;
2024-05-30 Audited Results
2024-02-14 Quarterly Results

Kabra Drugs FAQs

What is Share Price of Kabra Drugs ?

Kabra Drugs share price is ₹9 As on 05 November, 2024 | 08:38

What is the Market Cap of Kabra Drugs ?

The Market Cap of Kabra Drugs is ₹9.2 Cr As on 05 November, 2024 | 08:38

What is the P/E ratio of Kabra Drugs ?

The P/E ratio of Kabra Drugs is -7.9 As on 05 November, 2024 | 08:38

What is the PB ratio of Kabra Drugs ?

The PB ratio of Kabra Drugs is -6.3 As on 05 November, 2024 | 08:38

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23